Home › Funds › Opaleye Management Inc. › LYEL
Opaleye Management Inc. position in LYEL
LYELL IMMUNOPHARMA INC · Health Care
Opaleye Management Inc. reported holding 344,025 shares of LYEL (LYELL IMMUNOPHARMA INC) in its Q2 2026 13F filing — a position valued at US$4.8M, representing 0.44% of its reported portfolio and ranking #35 among its reported holdings. Opaleye Management Inc. has disclosed LYEL holdings in 5 of the last 10 reported quarters, going back to Q1 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Opaleye Management Inc.'s LYEL position evolved
Opaleye Management Inc. first disclosed a stake in LYEL in Q1 2024 at 3,355,000 shares (US$7.5M). Across 5 filings, Opaleye Management Inc. increased the stake 1 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 344,025 shares valued at US$4.8M — an increase of 264,928 shares quarter over quarter.. Notable position changes include a 50% trim in Q2 2024 (shares fell 5% over the following quarter), a 335% increase in Q2 2026 (shares fell 30% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 3.35M | $7.48M | New |
| Q2 2024 | 1.67M | $2.42M | Reduce |
| Q3 2024 | 1.40M | $1.93M | Reduce |
| Q1 2026 | 79.10K | $1.59M | New |
| Q2 2026 | 344.02K | $4.83M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About LYEL and 13F data
LYEL (LYELL IMMUNOPHARMA INC) is a Health Care company. 31 other funds we track also report a position in LYEL — the largest reported positions include ARCH Venture Management, LLC (US$45.5M), GSK plc (US$21.3M), Orland Properties Ltd (US$10.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding LYEL
- ARCH Venture Management, LLC 3.25M sh · $45.53M · Q2 2026
- GSK plc 1.51M sh · $21.25M · Q2 2026
- Orland Properties Ltd 754.70K sh · $10.60M · Q2 2026
- Decheng Capital LLC 692.05K sh · $9.72M · Q2 2026
- Almitas Capital LLC 581.41K sh · $8.17M · Q2 2026
- Foresite Capital Management V, LLC 476.39K sh · $6.69M · Q2 2026
- venBio Partners LLC 337.70K sh · $4.74M · Q2 2026
- Alphabet Inc. 293.26K sh · $4.12M · Q2 2026
- HSG Holding Ltd 152.30K sh · $2.14M · Q2 2026
- Velan Capital Investment Management LP 105.00K sh · $1.48M · Q2 2026
- MIC Capital Management UK LLP 87.03K sh · $1.22M · Q2 2026
More on Opaleye Management Inc.
FAQ
How long has Opaleye Management Inc. held LYEL?
Opaleye Management Inc. has disclosed LYEL holdings in 5 of the last 10 reported quarters, going back to Q1 2024.
What is Opaleye Management Inc.'s current position in LYEL?
As of Q2 2026, Opaleye Management Inc. holds 344.02K shares of LYEL (LYELL IMMUNOPHARMA INC), valued at $4.83M, representing 0.44% of its reported portfolio and ranking #35.
Has Opaleye Management Inc. been buying or selling LYEL?
In the latest 13F filing (Q2 2026), Opaleye Management Inc. increased its position in LYEL.
Which other funds hold LYEL?
Other major institutional holders of LYEL include ARCH Venture Management, LLC, GSK plc, Orland Properties Ltd, among 31 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.